BR112023024873A2 - Composto derivado de oxazol, composição farmacêutica compreendendo o mesmo, uso do composto derivado de oxazol e composição de alimento para melhorar os sintomas de doenças alérgicas - Google Patents

Composto derivado de oxazol, composição farmacêutica compreendendo o mesmo, uso do composto derivado de oxazol e composição de alimento para melhorar os sintomas de doenças alérgicas

Info

Publication number
BR112023024873A2
BR112023024873A2 BR112023024873A BR112023024873A BR112023024873A2 BR 112023024873 A2 BR112023024873 A2 BR 112023024873A2 BR 112023024873 A BR112023024873 A BR 112023024873A BR 112023024873 A BR112023024873 A BR 112023024873A BR 112023024873 A2 BR112023024873 A2 BR 112023024873A2
Authority
BR
Brazil
Prior art keywords
oxazole
compound derived
pharmaceutical composition
same
symptoms
Prior art date
Application number
BR112023024873A
Other languages
English (en)
Inventor
Ji Kim Eun
Hee Jang Geon
Soon Kim Ho
Hyun Son Sang
Hyeong Lim Tae
Ho Jeon Young
Joo Byun Young
Original Assignee
Azcuris Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azcuris Co Ltd filed Critical Azcuris Co Ltd
Publication of BR112023024873A2 publication Critical patent/BR112023024873A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/304Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

composto derivado de oxazol, composição farmacêutica compreendendo o mesmo, uso do composto derivado de oxazol e composição de alimento para melhorar os sintomas de doenças alérgicas. a presente invenção refere-se a um derivado inovador de oxazol, um método de preparação para o mesmo e uma composição farmacêutica que compreende o mesmo como um ingrediente ativo para prevenir ou tratar uma doença alérgica, tais como asma ou atopia. o derivado inovador de oxazol da presente invenção exibe um excelente efeito inibidor na sinalização intracelular de il-33 e, assim, pode ser usado vantajosamente como uma composição farmacêutica para a prevenção ou o tratamento de uma doença alérgica, tal como asma ou atopia.
BR112023024873A 2021-06-01 2022-05-31 Composto derivado de oxazol, composição farmacêutica compreendendo o mesmo, uso do composto derivado de oxazol e composição de alimento para melhorar os sintomas de doenças alérgicas BR112023024873A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210071013 2021-06-01
PCT/KR2022/007712 WO2022255764A1 (ko) 2021-06-01 2022-05-31 신규 옥사졸 유도체 및 이를 포함하는 알러지성 질환의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
BR112023024873A2 true BR112023024873A2 (pt) 2024-02-15

Family

ID=84324408

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024873A BR112023024873A2 (pt) 2021-06-01 2022-05-31 Composto derivado de oxazol, composição farmacêutica compreendendo o mesmo, uso do composto derivado de oxazol e composição de alimento para melhorar os sintomas de doenças alérgicas

Country Status (10)

Country Link
US (1) US20240287052A1 (pt)
EP (1) EP4349818A1 (pt)
JP (1) JP2024521807A (pt)
KR (1) KR20220162640A (pt)
CN (1) CN117396465A (pt)
AU (1) AU2022283883A1 (pt)
BR (1) BR112023024873A2 (pt)
CA (1) CA3220193A1 (pt)
MX (1) MX2023014205A (pt)
WO (1) WO2022255764A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002248432A1 (en) * 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
GB0820819D0 (en) * 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
EP2440555B1 (en) 2009-06-09 2016-05-18 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives
EP3567044A4 (en) * 2017-01-06 2020-06-10 Korea University Research and Business Foundation, Sejong Campus INNOVATIVE CHINOLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALLERGIC DISEASES LIKE ASTHMA OR ATOPIA THEREFORE AS AN ACTIVE SUBSTANCE
WO2018217766A1 (en) * 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof

Also Published As

Publication number Publication date
MX2023014205A (es) 2024-01-18
CN117396465A (zh) 2024-01-12
EP4349818A1 (en) 2024-04-10
US20240287052A1 (en) 2024-08-29
CA3220193A1 (en) 2022-12-08
KR20220162640A (ko) 2022-12-08
JP2024521807A (ja) 2024-06-04
WO2022255764A1 (ko) 2022-12-08
AU2022283883A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
BR112022002991A2 (pt) Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
BR112021023814A2 (pt) Inibidores de proteases de cisteína e métodos de uso das mesmas
BR112022000965A2 (pt) Derivado de adenosina e composição farmacêutica que compreende o mesmo
BR112023015527A2 (pt) Inibidores de cdk e métodos de uso destes
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
BR112019008458A2 (pt) 1,2,4-triazolonas 2,4,5-trisubstituídas.
BR112019009529A2 (pt) novos derivados de quinolina
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112022019057A2 (pt) Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune
BR112013011634A2 (pt) derivados de 2,3-di-hidroimidazol[1,2-c]quinazolina substituídos por aminoálcool úteis para tratar os distúrbios hiperproliferativos e as doenças associadas com a angiogênese derivados de 2,3-di-hidroimidazol[1,2-c]
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112022009409A2 (pt) Novos derivados que têm grupamento 2,3-dihidro-1h-indeno ou 2,3-dihidrobenzofurano ou sal farmaceuticamente aceitável dos mesmos e composições farmacêuticas que os compreendem
BR112012006010A2 (pt) composto de glicina
BR112023022451A2 (pt) Composto triazina substituído
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112021024325A2 (pt) Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
BR112022001567A2 (pt) Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112022025946A2 (pt) Composto, composição farmacêutica e método de tratamento de uma doença
BR112023026976A2 (pt) Inibidores do inflamassoma nlrp3
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112023024873A2 (pt) Composto derivado de oxazol, composição farmacêutica compreendendo o mesmo, uso do composto derivado de oxazol e composição de alimento para melhorar os sintomas de doenças alérgicas
BRPI0708554B8 (pt) uso de um composto
BR112022025191A2 (pt) Compostos de imidazopiridazina com atividade de inibidores de alk2